Deutetrabenazine in Tics Associated with Tourette Syndrome

• DOI: 10.5334/tohm.287
• Publication Date: 2020-06-24T11:19:36Z
• Authors: Joseph Jankovic; Joohi Jimenez-Shahed; Cathy Budman; Barbara Coffey; Tanya Murphy; David Shprecher; David Stamler
• Keywords: Clinical Global Impression; Tolerability; Tetrabenazine

<strong>Background:</strong> Deutetrabenazine, an inhibitor of vesicular monoamine transporter type 2 (VMAT2) depletes presynaptic dopamine and is useful in the treatment hyperkinetic movement disorders. This study explored safety, tolerability, preliminary efficacy deutetrabenazine adolescents with moderate-to-severe tics associated Tourette syndrome (TS). <strong>Methods:</strong> In this open-label 12–18-year-old patients TS-related tics, was titrated up to 36 mg/day over 6 weeks adequately suppress without bothersome adverse effects (AEs), followed by maintenance at optimal dose for weeks. An independent blinded rater assessed tic severity using Yale Global Tic Severity Scale (YGTSS), which primary outcome measure. Secondary measures included TS Clinical Impression (TS-CGI) Patient Change (TS-PGIC). <strong>Results:</strong> Twenty-three enrolled received had least 1 post-baseline YGTSS assessment. The mean (SD [standard deviation]) baseline Total Score (TTS) 31.6 (7.9) decreased 11.6 (8.2) points week 8, a 37.6% reduction (p,0.0001). TS-CGI score improved 1.2 (0.81) (p,0.0001) TS-PGIC results 8 indicated that 76% were much or very compared baseline. (SD) daily 32.1 (6.6) mg (range 18–36 mg). One after withdrawal deutetrabenazine, TTS scores increased 5.6 (8.4) points, providing confirmation drug effect. No serious severe events reported. <strong>Discussion:</strong> 8-week suggest safe improvement troublesome tics.